3h
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...
Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback